Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Dec 20, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, press-release
TL;DR
Innate Pharma dropped a 6-K filing on 12/20/24, likely with a press release attached.
AI Summary
Innate Pharma SA filed a Form 6-K on December 20, 2024, reporting a press release dated the same day. The filing does not contain specific financial figures or operational updates but serves as a notification to the SEC.
Why It Matters
This filing indicates Innate Pharma is providing an update or making an announcement to the SEC, which could be relevant for investors monitoring the company's communications.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not contain new material financial or operational information that would immediately impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- December 20, 2024 (date) — Filing date and press release date
- 001-39084 (other) — SEC File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information that the company has made or is required to make public in its home country, filed with or made to any stock exchange, or distributed to its security holders.
What specific information is included in this 6-K filing?
This 6-K filing primarily includes a press release dated December 20, 2024, as Exhibit 99.1, and indicates that Innate Pharma S.A. is a foreign private issuer filing under the 1934 Act.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on December 20, 2024.
What is the principal executive office of Innate Pharma S.A.?
The principal executive office of Innate Pharma S.A. is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma S.A. file annual reports on Form 20-F or Form 40-F?
Innate Pharma S.A. indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-12-20 07:03:21
Filing Documents
- a6k-iphx241220.htm (6-K) — 8KB
- exhibit991-241220.htm (EX-99.1) — 16KB
- 0001598599-24-000100.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date December 20, 2024 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chairman of the Executive Board and Chief Executive officer